Version May 2024
Neurotrophic keratitis: Instill 1 drop into affected eye(s) 6 times daily at 2-hour intervals for 8 weeks.
Missed dose: If a dose is missed, continue treatment at the next scheduled administration.
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
(For additional information see "Cenegermin: Pediatric drug information")
Neurotrophic keratitis: Children ≥2 years and Adolescents: Instill 1 drop into the affected eye(s) every 2 hours for 6 doses daily for 8 weeks
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
>10%: Ophthalmic: Eye pain (16%)
1% to 10%:
Nervous system: Headache
Ophthalmic: Corneal deposits, foreign body sensation of eye, lacrimation, ocular hyperemia, ophthalmic inflammation, photophobia
Postmarketing: Ophthalmic: Blepharitis (including crusting of eyelid [margin], eyelid edema), corneal disease (corneal neovascularization), eye irritation
There are no contraindications listed in the manufacturer's labeling.
Concerns related to adverse effects:
• Ocular effects: May cause mild to moderate eye discomfort (eg, eye pain); notify health care professional if more serious eye reactions occur.
Special populations:
• Contact lens wearers: Remove contact lenses prior to administration and wait 15 minutes before reinserting.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic [preservative free]:
Oxervate: Cenegermin-bkbj 0.002% (1 mL)
No
Solution (Oxervate Ophthalmic)
0.002% (per mL): $2,273.00
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic:
Oxervate: Cenegermin-bkbj 0.002% (1 mL)
Ophthalmic: If more than one topical ophthalmic drug is being used, administer the drugs at least 15 minutes apart; administer cenegermin 15 minutes prior to any eye ointment, gel, or other viscous eye drops. Remove contact lenses prior to administration and wait 15 minutes before reinserting. Pull down lower eyelid and administer into the conjunctival fornix (space between inner eyelid and eyeball). Keep head tilted back and blink a few times so the surface of the eye is covered. Discard pipette immediately after use and use a new pipette for each eye and administration. See manufacturer's labeling for detailed administration.
Ophthalmic: Prior to dispensing, weekly carton is kept frozen. If treatment is initiated immediately after receiving the weekly carton, vials may still be frozen and first vial must be thawed (may take up to 30 minutes at room temperature). Attach vial adapter to vial. Clean surface of valve on the connector part of the vial adapter; wait ~1 minute and screw pipette (clockwise) into the connector part of the vial adapter; make sure plunger is pushed all the way down. Invert vial and gently pull pipette plunger until it stops (to draw the eye drop solution into the pipette). After the pipette has been correctly filled, unscrew pipette (counter-clockwise) from the connector part of the vial adapter.
Wash hands before use; pull down lower eyelid and administer into the conjunctival fornix (space between inner eyelid and eyeball). Blink a few times so the surface of the eye is covered. Discard pipette immediately after use. If using drops in both eyes, use new pipette for each eye. See manufacturer's labeling for detailed administration. Remove contact lenses prior to instillation and wait at least 15 minutes before reinserting. If more than one topical ophthalmic medication is being used, separate administration of other ophthalmic products by at least 15 minutes to avoid dilution of products; administer cenegermin at least 15 minutes prior to eye ointment, gel, or other viscous eye drops. If a dose is missed, continue treatment at the next scheduled administration.
Neurotrophic keratitis: Treatment of neurotrophic keratitis
None known.
There are no known significant interactions.
Adverse events were not observed in animal reproduction studies.
It is not known if cenegermin is present in breast milk following ophthalmic application.
According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.
Nerve growth factor is an endogenous protein involved in the differentiation and maintenance of neurons, which acts through specific high-affinity (ie, TrkA) and low-affinity (ie, p75NTR) nerve growth factor receptors in the anterior segment of the eye to support corneal innervation and integrity.
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
